Market capitalization | $2.32b |
Enterprise Value | $1.86b |
P/E (TTM) P/E ratio | 14.62 |
EV/FCF (TTM) EV/FCF | 8.13 |
EV/Sales (TTM) EV/Sales | 5.76 |
P/S ratio (TTM) P/S ratio | 7.17 |
P/B ratio (TTM) P/B ratio | 4.36 |
Revenue (TTM) Revenue | $323.80m |
EBIT (operating result TTM) EBIT | $149.11m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
11 Analysts have issued a Protagonist Therapeutics, Inc. forecast:
11 Analysts have issued a Protagonist Therapeutics, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 324 324 |
-
|
|
Gross Profit | 321 321 |
11,801%
11,801%
|
|
EBITDA | 152 152 |
201%
201%
|
EBIT (Operating Income) EBIT | 149 149 |
197%
197%
|
Net Profit | 171 171 |
222%
222%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Protagonist Therapeutics, Inc. engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
Head office | United States |
CEO | Dinesh Patel |
Employees | 112 |
Founded | 2006 |
Website | www.protagonist-inc.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.